VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to enhance the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company, which recently began trading on the NASDAQ Capital Market under the ticker VRXA after completing a business combination with Voyager Acquisition Corp., is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results suggest the potential for improved precision in antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
The company maintains a diversified oncology pipeline of antibody-based formats including ADCs, T-cell engagers (TCEs), and other antibody-based formats. The announcement comes as VERAXA prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, including those set forth in the company’s filings with the SEC. All parties undertake no duty to update this information unless required by law.
